The shares of Inari Medical Inc. have ceased trading, concluding its journey as a publicly listed company. This development follows the medical device firm’s acquisition by the larger industry player, Stryker Corporation. The deal, initially announced in January 2025 and finalized the following month, carried a total value of $4.9 billion. Consequently, Inari Medical has been delisted from the NASDAQ exchange, fully absorbed into Stryker’s corporate structure.
A Strategic Acquisition for Stryker’s Portfolio
Stryker’s move was a strategic play to bolster its position in two key areas: neurovascular and peripheral vascular markets. A central component of this strategy is enhancing treatment options for venous thromboembolism (VTE). Inari Medical brought to the table its established, minimally invasive thrombectomy platforms, namely the ClotTriever and FlowTriever systems. These catheter-based devices enable the removal of large blood clots in conditions like deep vein thrombosis and pulmonary embolism without the need for surgery.
The acquisition price of $80 per share represented a significant premium to Inari’s trading levels prior to the deal’s announcement. Market analysts at the time pointed to the company’s robust revenue growth and its leadership in the VTE segment to justify the valuation. For the 2024 fiscal year, Inari was projected to generate sales of approximately $603 million, a notable increase from the $494 million reported for the previous year.
Should investors sell immediately? Or is it worth buying Inari Medical Inc?
Transaction Details and Integration Path
Stryker completed the purchase using cash, paying $80 for each outstanding share of Inari Medical. The final trading price settled at around $79.97. The boards of directors for both companies voted unanimously in favor of the transaction.
The integration process is now underway. Inari’s technologies, which also include the InThrill system for small vessels and the LimFlow system for chronic limb-threatening ischemia, are seen as complementary to Stryker’s existing portfolio for peripheral vascular disease. A key advantage of Inari’s mechanical thrombectomy approach is its potential to reduce bleeding risks and often eliminate the need for thrombolytic drugs.
Looking ahead, Stryker plans to leverage its global commercial infrastructure to significantly expand the reach and impact of these innovations. The financial effects of the acquisition will be detailed in Stryker’s future earnings reports. The focus now shifts to how Stryker will utilize Inari’s expertise to accelerate the development of new vascular solutions and access additional markets.
Ad
Inari Medical Inc Stock: Buy or Sell?! New Inari Medical Inc Analysis from December 12 delivers the answer:
The latest Inari Medical Inc figures speak for themselves: Urgent action needed for Inari Medical Inc investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 12.
Inari Medical Inc: Buy or sell? Read more here...
